Current Topics in Clinical Pharmacogenomics

Program Details

  • Intended Audience: Pharmacists interested in pharmacogenomics
  • Universal Activity Number: 0012-0000-20-030-H04-P
  • Contact Hours: 3
  • Program Fees: $50.00
  • Dates Available: 05/06/2020 – 05/06/2023
  • Activity Type: Knowledge


Learn from leading experts in the field of pharmacogenomics. This program focuses on the latest evidence-based data and the emerging hot topics related to pharmacogenomics. It will also discuss how to interpret pharmacogenomics test results and identify challenges associated with the use of activity scores in clinical pharmacogenomics. Content is based on the Precision Medicine Conference hosted February 2020.

This course is approved by the Florida Board of Pharmacy for 3 consultant recertification hours.


At the completion of this activity, the participant will be able to:

  • Describe the current state of knowledge and emerging trends in precision medicine across a broad range of therapeutic areas including pharmacogenomics, preventive disease risk assessment, universal genomic screening, newborn screening, precision oncology, and the use of microbial genomics in infection control.
  • Demonstrate the regulatory oversight and need for application of evidence-based medicine principles in precision medicine and clinical pharmacogenomics.
  • Describe challenges and solutions for the application of precision medicine in patient care. 
  • Compare and contrast approaches to implementing precision medicine in a variety of clinical settings.

Disclosure Statement

The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

  • Michael Pacanowski, Pharm.D., M.P.H
  • Jordan Baye, Pharm.D., MA
  • Roseann Gammal, Pharm.D., R.Ph., BCPS
  • Emily Cicali, Pharm.D.
  • D. Maxwell Smith III, Pharm.D., BCPS
  • Kelly Caudle, Pharm.D., Ph.D., BCPS, FCCP

The following speakers, reviewers, and planning committee members have disclosed the following:

  • J. Kevin Hicks, Pharm.D., Ph.D. has disclosed he is a consultant for Novartis, Quest Diagnostics, 23andMe, and Medstar Health System, and has received grant/ research support from OneOme.
  • Cameron Thomas, Pharm.D. has disclosed he has received grant/ research support from NIH NHGRI 1T32HG008958-01A1 grant.

Schedule of Activities and Requirements for Successful Course Completion

Review the course material, receive a 70% or higher on the post-test, and submit a course evaluation.

Additional Resources

Please review the resources below before registering for the course.

ACPE logo

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.